Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kura Oncology, Inc.KURA · Entity 4871 | Chief Medical Officer | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kura Oncology, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 182,345 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Sale · Disposed 84,929 · Balance 182,345 F1: The shares sold were acquired by the Reporting Person upon vesting of restricted stock units and performance restricted stock units during the period from January 26, 2022 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2: This transaction was executed in multiple trades at prices ranging from $9.56 to $9.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares sold were acquired by the Reporting Person upon vesting of restricted stock units and performance restricted stock units during the period from January 26, 2022 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $9.56 to $9.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 22:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 84,929 | $9.82 | $834,283.05 |
DisclosureSEC source: 0001193125-26-277780 · ownership.xml · nonDerivative · entry 1 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,345 F1 · kind: The shares sold were acquired by the Reporting Person upon vesting of restricted stock units and performance restricted stock units during the period from January 26, 2022 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.56 to $9.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,341 | $8.46 | $11,345.80 |
DisclosureSEC source: 0001193125-26-025303 · ownership.xml · nonDerivative · entry 4 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,274 F4 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 951 | $8.46 | $8,046.13 |
DisclosureSEC source: 0001193125-26-025303 · ownership.xml · nonDerivative · entry 3 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,615 F3 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,233 | $8.46 | $18,892.74 |
DisclosureSEC source: 0001193125-26-025303 · ownership.xml · nonDerivative · entry 2 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,566 F2 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/24. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 3,655 | $8.46 | $30,923.86 |
DisclosureSEC source: 0001193125-26-025303 · ownership.xml · nonDerivative · entry 1 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,799 F1 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 100,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004570 · ownership.xml · derivative · entry 2 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004570 · ownership.xml · nonDerivative · entry 1 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,454 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 15,485 | $11.18 | $173,074.30 |
DisclosureSEC source: 0001193125-25-283563 · ownership.xml · nonDerivative · entry 2 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,454 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023 and January 2, 2025. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 82,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-283563 · ownership.xml · nonDerivative · entry 1 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,939 Read SEC document |
| September 29, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 12,314 | $8.94 | $110,114.25 |
DisclosureSEC source: 0001193125-25-223664 · ownership.xml · nonDerivative · entry 2 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,439 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023 and January 2, 2025. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on September 27, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| September 27, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 82,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-223664 · ownership.xml · nonDerivative · entry 1 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,753 Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:39 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 541 | $7.87 | $4,258.70 |
DisclosureSEC source: 0000950170-25-010121 · ownership.xml · nonDerivative · entry 4 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,253 F4 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/21. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:39 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 816 | $7.87 | $6,423.47 |
DisclosureSEC source: 0000950170-25-010121 · ownership.xml · nonDerivative · entry 3 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,794 F3 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:39 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,353 | $7.87 | $10,650.68 |
DisclosureSEC source: 0000950170-25-010121 · ownership.xml · nonDerivative · entry 2 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,610 F2 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:39 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,253 | $7.87 | $17,735.39 |
DisclosureSEC source: 0000950170-25-010121 · ownership.xml · nonDerivative · entry 1 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,963 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 22:48 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 92,500 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001415889-25-001052 · form4-01072025_100104.xml · derivative · entry 2 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2035-01-01 F2 · derivative.exercise_date: The option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 22:48 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001052 · form4-01072025_100104.xml · nonDerivative · entry 1 Leoni Mollie · CIK 0002051106 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,216 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/26, 1/26/27, 1/26/28 and 1/26/29. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.